Provider Barriers in Uptake of Biosimilars: Case Study on Filgrastim
Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings.
Changes in Opioid Marketing Practices After Release of the CDC Guidelines
After the CDC guidelines’ release, total opioid marketing spending and encounters per physician decreased, but spending per encounter subsequently increased.
Site of Care Potentially Limits Cost Savings From Biosimilars
Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings.
2 Clarke Drive Cranbury, NJ 08512